Subscriber Login
DRIP Tools
List of No-Loads and theirQuadrix ratings
Intermediate Potential Risk Indicator
DRIP Ratings & Web site links
DRIP Investor Picks Stocks That Go Up!
Every month, DRIP Investor directs you to the best stocks carefully selected from among the 1,100+ companies that offer dividend reinvestment plans.
Each issue even features our single best idea (our "DRIP Analyst" selection) for making money in DRIPs.
And in other highly focused feature articles (see Paychex, "DRIPs With Zip" below) we regularly point DRIP Investor subscribers to other high-profit opportunities.
You see, we think it’s our job — in our selection process — to point you to the very best of the many good companies that offer these plans.
Will our selection process work for you? See for yourself!
| Paychex, another "DRIP With Zip" selection, was featured at the split-adjusted price of less than $3 in the June 1994 issue. | UP 1548% . . . in 6 1/2 years. |
| Intel, highlighted in a June, 1994 feature article as a "DRIP With Zip." | UP 756% . . . in 6 1/2 years. |
| IBM was highlighted in the November 1993 DRIP Investor as an insider buying favorite when the stock was drifting badly. As it turns out, the insiders were right! | UP 688% a little over 7 years. |
| Walgreen has been an outstanding performer since its recommendation in the May 1996 issue of DRIP Investor. | UP 391% . . . in less than 5 years. |
| Johnson & Johnson was a "DRIP Analyst" selection from the August, 1994 DRIP Investor. | UP 320% . . . in a little over 6 years. |
And, more recently, Walgreen jumped 206% in a little over 3 years, Warner-Lambert shot up 145% in 29 months, AT&T rose 108% in 24 months, BellSouth leaped 101% in 21 months.
You need to see for yourself. Subscribe to DRIP Investor today.
ATTENTION
Wall Street Journal Readers
Your FREE LIST of No-Load Stocks
Commentary
5/12/08
Where To Go For Health Care
Charles Carlson, CFA
Editor, DRIP Investor Newsletter
I remember when I first started in this business more than a quarter century ago, one group that was regarded as a “sure thing” for gains was health care, especially pharmaceutical stocks.
Well, things have certainly changed over the years. Indeed, pharmaceutical stocks have had plenty of problems in recent years. Generic competition, the lack of blockbuster drugs, and health concerns with existing medications have all served to dampen pharma stocks.